CNBC's "Fast Money" Stocks Sell Off On President Trump’s China Threat… And A New Drug Price Deal 10/10/25
Oct 10, 2025
DeWardrick McNeil, a senior policy analyst and former Obama official, discusses the market fallout from President Trump's controversial 100% tariffs on China. He explains the ripple effects on tech and semiconductor stocks, mentioning parallels to past tariff panic. McNeil also sheds light on the implications of China's rare earth materials in geopolitics and supply chains. Additionally, he delves into the new drug pricing deal with AstraZeneca, evaluating its impact on the pharmaceutical landscape and potential shifts in investor confidence.
AI Snips
Chapters
Transcript
Episode notes
Delay Aggressive Dip‑Buying; Shift To Defensives
- Mike Coe recommended waiting for more clarity before aggressively buying dips given the government shutdown, technical reversal, and high valuations.
- He suggested shifting toward safety trades like utilities and staples during the uncertainty.
Gold Rally Signals Geopolitical Market Shifts
- Tim Seymour and panel noted rising gold and a softer dollar as market/geo tensions increased, which strengthens China's alternative levers.
- That dynamic can complicate U.S. policy responses and market behavior.
China Using Built Legal Tools For Maximum Leverage
- DeWardrick McNeil warned China activated a legal architecture for export controls built over years to maximize leverage now.
- He urged focusing on breaking China's chokehold on critical minerals and upstream supply chains.